(Q43686388)

25 November 2017

title

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study (English)

1 reference

25 November 2017

1 reference

1

1 reference

25 November 2017

8

M Julia Brosnan

1 reference

25 November 2017

Ho-Youn Kim

2

1 reference

25 November 2017

Sang-Heon Lee

3

1 reference

25 November 2017

David Mandel

4

1 reference

25 November 2017

Yeong-Wook Song

5

1 reference

25 November 2017

Carol A Connell

6

1 reference

25 November 2017

Zhen Luo

7

1 reference

25 November 2017

Andrea Zuckerman

9

1 reference

25 November 2017

Samuel H Zwillich

10

1 reference

25 November 2017

John D Bradley

11

1 reference

25 November 2017

language of work or name

English

0 references

publication date

12 March 2013

1 reference

Annals of the Rheumatic Diseases

25 November 2017

published in

1 reference

25 November 2017

volume

73

1 reference

25 November 2017

issue

1

1 reference

25 November 2017

page(s)

124-131

1 reference

The pathogenesis of rheumatoid arthritis

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Treatment of rheumatoid arthritis: state of the art 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

'Rac'-ing upstream to treat rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Particle size: the key to the atherogenic lipoprotein?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Mechanisms for the anti-inflammatory effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Current and novel therapeutics in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Statins accelerate the onset of collagen type II-induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202442

10.1136/ANNRHEUMDIS-2012-202442

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference